In conclusion, this study was the first to discover that patients with luminal A breast cancer carrying SNP rs6484711 variant A allele at ABTB2 5′UTR can significantly reduce the effectiveness of epirubicin combined with docetaxel by regulating the expression of ABTB2 protein. Here, ABTB2 is linked to breast carcinoma.